Bioxcel therapeutics to host virtual neuroscience r&d day on dec. 12, 2023

Company to review bxcl502 and other potential emerging pipeline candidates   dr. jeffrey cummings to discuss agitation relief in alzheimer's disease and bxcl502 as a potential treatment dr. sandra comer to discuss bxcl501 as a potential treatment for opioid withdrawal  new haven, conn., nov. 30, 2023 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a virtual neuroscience r&d day from 1:00 to 2:30 p.m.
BTAI Ratings Summary
BTAI Quant Ranking